The second pathway is the kinin pathway, most notably affected by angiotensin converting enzyme (ACE) inhibitors and hereditary forms of angioedema with C1-esterase inhibitor defects, which ultimately results in the formation of bradykinin, a potent vasodilator. This evidence concerns the gene ACE and angioedema.